Roche won't help to make Avastin available for AMD in France
This article was originally published in SRA
Roche is refusing to play any part in French government efforts to make its anticancer Avastin available for off-label use in wet AMD under a "temporary use recommendation" (RTU), saying that it goes against the product's labeling and that other therapeutic alternatives are already available1.
You may also be interested in...
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.